Needelman Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Needelman Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,210	Closed	-$520K	–	38
2017 Q1	$520K	Sell	16,210 -70	-0.4%	-$2.39K	1.39%	35
2016 Q4	$590K	Sell	16,280 -1,120	-6%	-$44.7K	1.64%	35
2016 Q3	$801K	Sell	17,400 -500	-3%	-$26.1K	2.41%	25
2016 Q2	$899K	Hold	17,900	–	–	2.57%	19
2016 Q1	$958K	Hold	17,900	–	–	2.8%	17
2015 Q4	$1.18M	Sell	17,900 -90	-0.5%	-$5.56K	3.57%	10
2015 Q3	$1.02M	Hold	17,990	–	–	3.34%	11
2015 Q2	$1.06M	Sell	17,990 -435	-2%	-$26.8K	3.36%	9
2015 Q1	$1.15M	Sell	18,425 -50	-0.3%	-$2.91K	3.48%	8
2014 Q4	$1.06M	Hold	18,475	–	–	3.25%	12
2014 Q3	$993K	Sell	18,475 -185	-1%	-$9.8K	3.18%	11
2014 Q2	$978K	Hold	18,660	–	–	3.09%	13
2014 Q1	$986K	Sell	18,660 -250	-1%	-$11.6K	3.2%	10
2013 Q4	$758K	Sell	18,910 -245	-1%	-$9.65K	2.5%	25
2013 Q3	$724K	Sell	19,155 -125	-0.6%	-$4.88K	2.59%	22
2013 Q2	$756K	Buy	+19,280	New	+$751K	2.76%	16

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Needelman Asset Management's TEVA Position: Q2 2017 in Review

Needelman Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 16,210 shares — an estimated $520K sold.

Needelman Asset Management first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $1.18M in Q4 2015. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Needelman Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Needelman Asset Management sold 16,210 Teva Pharmaceuticals shares in Q2 2017, an estimated $520K.
Needelman Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Needelman Asset Management's Teva Pharmaceuticals position peaked at $1.18M in Q4 2015.
649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Needelman Asset Management's 13F filing for Q2 2017, filed 7 Jul 2017.